PharmaTher Nears FDA Decision on Ketamine Application

PharmaTher Holdings Ltd (TSE:PHRM) has released an update.

PharmaTher Holdings Ltd., a specialty pharmaceutical company, has received a Generic Drug User Fee Amendments goal date of October 29, 2024, from the FDA for its Ketamine drug application. The company has addressed previous FDA concerns and is aiming to solve the U.S. ketamine shortage, with plans to pursue international approvals post-launch. PharmaTher’s broader strategy includes exploring new uses and delivery methods for ketamine to treat pain, mental health, and neurological disorders.

For further insights into TSE:PHRM stock, check out TipRanks’ Stock Analysis page.